A phase I/IIa, single and multiple ascending dose, randomized, double-blind, placebo-controlled clinical trial of SYNB1618 for the treatment of phenylketonuria (PKU)
Phase of Trial: Phase I/II
Latest Information Update: 18 Apr 2018
At a glance
- Drugs SYNB-1618 (Primary)
- Indications Phenylketonuria
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 18 Apr 2018 Accotrding to a Synlogic media release, first patient has been dosed.
- 18 Apr 2018 Status changed from planning to recruiting, according to a Synlogic media release.
- 18 Apr 2018 Accotrding to a Synlogic media release, interim data from the SAD (Part 1) portion is expect in 2018 and the full data is expected in 2019.